Literature DB >> 23461306

Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine.

Hala Nsouli-Maktabi1, Sharon L Ludwig, Uma D Yerubandi, Joel C Gaydos.   

Abstract

Human papillomavirus (HPV) is the most common sexually transmitted infection among U.S. military members. The most frequent clinical manifestation of HPV is genital warts (GW). This investigation examined the annual incidence of diagnoses of GW among U.S. service members before and after the availability of the quadrivalent HPV (HPV4) vaccine in 2006. Incidence rates of GW diagnoses markedly declined among female service members in the HPV4 vaccine-eligible age range from 2007 (following introduction of the HPV4 vaccine) through 2010. In contrast, among women 25 years and older and men of all age groups, annual rates of GW diagnoses remained relatively low and stable from 2000 through 2010. The higher rates of diagnoses of GWs among female than male service members reflect the effects of routine periodic gynecologic screening. Slight increases in the incidence of GW diagnoses among men between 2010 and 2012 may in part reflect the repeal of the U.S. military's "Don't Ask Don't Tell" policy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23461306

Source DB:  PubMed          Journal:  MSMR        ISSN: 2152-8217


  14 in total

1.  Human Papillomavirus Vaccination and Anogenital Warts: A Systematic Review of Impact and Effectiveness in the United States.

Authors:  Anthony E Yakely; Lital Avni-Singer; Carlos R Oliveira; Linda M Niccolai
Journal:  Sex Transm Dis       Date:  2019-04       Impact factor: 2.830

2.  Assessing sociodemographic differences in human papillomavirus vaccine impact studies in the United States: a systematic review using narrative synthesis.

Authors:  L R Avni-Singer; A Yakely; S S Sheth; E D Shapiro; L M Niccolai; C R Oliveira
Journal:  Public Health       Date:  2019-11-04       Impact factor: 2.427

3.  Prevalence of Human Papillomavirus Genotypes and Abnormal Pap Smears Among Women in the Military Health System.

Authors:  Christopher M Daly; Shana L Hansen; Paul O Kwon; Timothy A Roberts
Journal:  J Community Health       Date:  2018-06

4.  Seroprevalence and seroincidence of herpes simplex virus (2006-2010), syphilis (2006-2010), and vaccine-preventable human papillomavirus subtypes (2000-2010) among US military personnel.

Authors:  Jennifer Masel; Robert G Deiss; Xun Wang; Jose L Sanchez; Anuradha Ganesan; Grace E Macalino; Joel C Gaydos; Mark G Kortepeter; Brian K Agan
Journal:  Sex Transm Dis       Date:  2015-05       Impact factor: 2.830

5.  The factors associated with maternal consent to human papillomavirus vaccination among adolescents in Israel.

Authors:  Rana Shibli; Shmuel Rishpon
Journal:  Hum Vaccin Immunother       Date:  2019-07-24       Impact factor: 3.452

6.  Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Norma Pérez; Marc Brisson
Journal:  Lancet       Date:  2019-06-26       Impact factor: 79.321

7.  Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.

Authors:  Nelly Mugo; Nana Akosua Ansah; Deborah Marino; Alfred Saah; Elizabeth I O Garner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Trends in Genital Warts in the Era of Human Papillomavirus Vaccination.

Authors:  William A Calo; Noel T Brewer
Journal:  Sex Transm Dis       Date:  2015-12       Impact factor: 2.830

9.  The changing landscape of controlling sexually transmitted infections in the U.S. military.

Authors:  Joel C Gaydos; Kelly T McKee; Charlotte A Gaydos
Journal:  MSMR       Date:  2013-02

Review 10.  Impact of HPV vaccination on anogenital warts and respiratory papillomatosis.

Authors:  Zoon Wangu; Katherine K Hsu
Journal:  Hum Vaccin Immunother       Date:  2016-05-23       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.